Patents by Inventor Nadine OTTOSON

Nadine OTTOSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BETA GLUCAN IMMUNOPHARMACODYNAMICS
    Publication number: 20240019444
    Abstract: This disclosure provides, in one aspect, dosing strategies for soluble ?-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble ?-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-?-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.
    Type: Application
    Filed: September 19, 2023
    Publication date: January 18, 2024
    Inventors: Nandita Bose, Nadine Ottoson, Ben Harrison, Jamie Lowe, Mark Uhlik, Jeremy Graff, Richard Huhn
  • Beta glucan immunopharmacodynamics
    Patent number: 11815435
    Abstract: This disclosure provides, in one aspect, dosing strategies for soluble ?-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble ?-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-?-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: November 14, 2023
    Assignee: HiberCell, Inc.
    Inventors: Nandita Bose, Nadine Ottoson, Ben Harrison, Jamie Lowe, Mark Uhlik, Jeremy Graff, Richard Huhn
  • BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
    Publication number: 20220047620
    Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
    Type: Application
    Filed: March 29, 2021
    Publication date: February 17, 2022
    Inventors: Nandita Bose, Keith Gorden, Anissa SH. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton
  • BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
    Publication number: 20210283169
    Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
    Type: Application
    Filed: March 29, 2021
    Publication date: September 16, 2021
    Inventors: Nandita Bose, Keith Gorden, Anissa SH. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton
  • BETA GLUCAN IMMUNOPHARMACODYNAMICS
    Publication number: 20200033362
    Abstract: This disclosure provides, in one aspect, dosing strategies for soluble ?-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble ?-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-?-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.
    Type: Application
    Filed: February 23, 2018
    Publication date: January 30, 2020
    Applicant: BIOTHERA PHARMACEUTICALS, INC.
    Inventors: Nandita BOSE, Nadine OTTOSON, Ben HARRISON, Jamie LOWE, Mark UHLIK, Jeremy GRAFF, Richard HUHN
  • BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
    Publication number: 20190060350
    Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 28, 2019
    Inventors: Nandita BOSE, Keith GORDEN, Anissa SH. CHAN, Steven LEONARDO, Jeremy GRAFF, Xiaohong QIU, Takashi KANGAS, Kathryn A. FRASER, Adria BYKOWSKI JONAS, Nadine OTTOSON, Ross FULTON
  • BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
    Publication number: 20190060351
    Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 28, 2019
    Inventors: Nandita BOSE, Keith GORDEN, Anissa SH. CHAN, Steven LEONARDO, Jeremy GRAFF, Xiaohong QIU, Takashi KANGAS, Kathryn A. FRASER, Adria BYKOWSKI JONAS, Nadine OTTOSON, Ross FULTON
  • ?-glucan methods and compositions that affect the tumor microenvironment
    Patent number: 10111900
    Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 30, 2018
    Assignee: BIOTHERA, INC.
    Inventors: Nandita Bose, Keith Gorden, Anissa Sh. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton
  • Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
    Patent number: 10111901
    Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 30, 2018
    Assignee: BIOTHERA, INC.
    Inventors: Nandita Bose, Keith Gorden, Anissa S H. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton
  • BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
    Publication number: 20170100424
    Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 13, 2017
    Inventors: Nandita BOSE, Keith GORDEN, Anissa SH. CHAN, Steven LEONARDO, Jeremy GRAFF, Xiaohong QIU, Takashi KANGAS, Kathryn A. FRASER, Adria BYKOWSKI JONAS, Nadine OTTOSON
  • BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
    Publication number: 20170100425
    Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 13, 2017
    Inventors: Nandita BOSE, Keith GORDEN, Anissa SH. CHAN, Steven LEONARDO, Jeremy GRAFF, Xiaohong QIU, Takashi KANGAS, Kathryn A. FRASER, Adria BYKOWSKI JONAS, Nadine OTTOSON